{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:47:22Z","timestamp":1778042842173,"version":"3.51.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Taishan Scholars Program for Young Expert of Shandong Province","award":["tsqn20161064"],"award-info":[{"award-number":["tsqn20161064"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073200"],"award-info":[{"award-number":["82073200"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81874178"],"award-info":[{"award-number":["81874178"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"founds for Independent Cultivation of Innovative Team from Universities in Jinan","award":["2020GXRC023"],"award-info":[{"award-number":["2020GXRC023"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00432-022-04008-y","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T08:03:14Z","timestamp":1651132994000},"page":"1425-1441","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and security of tumor vaccines for hepatocellular carcinoma: a systemic review and meta-analysis of the last 2 decades"],"prefix":"10.1007","volume":"149","author":[{"given":"Cheng-Long","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chuan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lun-Jie","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang-Xiao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Cheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-Niu","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao-Ru","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Guo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Qiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5108-1774","authenticated-orcid":false,"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"issue":"2","key":"4008_CR1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/jgh.13449","volume":"32","author":"B Baradaran Noveiry","year":"2017","unstructured":"Baradaran Noveiry B, Hirbod-Mobarakeh A, Khalili N, Hourshad N, Greten TF, Abou-Alfa GK et al (2017) Specific immunotherapy in hepatocellular cancer: A systematic review. J Gastroenterol Hepatol 32(2):339\u2013351. https:\/\/doi.org\/10.1111\/jgh.13449","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"4008_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"4008_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h988","volume":"350","author":"LH Butterfield","year":"2015","unstructured":"Butterfield LH (2015) Cancer Vaccines Bmj 350:h988. https:\/\/doi.org\/10.1136\/bmj.h988","journal-title":"Cancer Vaccines Bmj"},{"issue":"9","key":"4008_CR4","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1158\/1078-0432.CCR-05-2856","volume":"12","author":"LH Butterfield","year":"2006","unstructured":"Butterfield LH, Ribas A, Dissette VB, Lee Y, Jin QY, De La Rocha P et al (2006) A phase I\/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four \u03b1-fetoprotein peptides. Clin Cancer Res 12(9):2817\u20132825. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-2856","journal-title":"Clin Cancer Res"},{"issue":"8","key":"4008_CR5","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.jcyt.2018.06.002","volume":"20","author":"C Chen","year":"2018","unstructured":"Chen C, Ma YH, Zhang YT, Zhang F, Zhou N, Wang X et al (2018) Effect of dendritic cell-based immunotherapy on hepatocellular carcinoma: a systematic review and meta-analysis. Cytotherapy 20(8):975\u2013989. https:\/\/doi.org\/10.1016\/j.jcyt.2018.06.002","journal-title":"Cytotherapy"},{"issue":"1","key":"4008_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/imm.12888","volume":"154","author":"M Collin","year":"2018","unstructured":"Collin M, Bigley V (2018) Human dendritic cell subsets: an update. Immunology 154(1):3\u201320. https:\/\/doi.org\/10.1111\/imm.12888","journal-title":"Immunology"},{"issue":"1","key":"4008_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00432-012-1298-8","volume":"139","author":"M El Ansary","year":"2013","unstructured":"El Ansary M, Mogawer S, Abd Elhamid S, Alwakil S, Aboelkasem F, El Sabaawy H et al (2013) Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC. J Cancer Res Clin Oncol 139(1):39\u201348. https:\/\/doi.org\/10.1007\/s00432-012-1298-8","journal-title":"J Cancer Res Clin Oncol"},{"key":"4008_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-209","author":"TF Greten","year":"2010","unstructured":"Greten TF, Forner A, Korangy F, N\u2019Kontchou G, Barget N, Ayuso C et al (2010) A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer. https:\/\/doi.org\/10.1186\/1471-2407-10-209","journal-title":"BMC Cancer"},{"issue":"5","key":"4008_CR9","first-page":"674","volume":"34","author":"W Guo","year":"2014","unstructured":"Guo W, Liu L, Wu D (2014) Dendritic cell-cytokine induced killer cell immunotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: safety and efficacy. Nan Fang Yi Ke Da Xue Xue Bao J Southern Med Univ 34(5):674\u2013678","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao J Southern Med Univ"},{"key":"4008_CR10","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.intimp.2016.09.015","volume":"40","author":"G He","year":"2016","unstructured":"He G, Zheng C, Huo H, Zhang H, Zhu Z, Li J et al (2016) TACE combined with dendritic cells and cytokine-induced killer cells in the treatment of hepatocellular carcinoma: a meta-analysis. Int Immunopharmacol 40:436\u2013442. https:\/\/doi.org\/10.1016\/j.intimp.2016.09.015","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"4008_CR11","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.7150\/jca.23725","volume":"9","author":"Y He","year":"2018","unstructured":"He Y, Guo Y, Chen J, Hu X, Li X, Kong Y et al (2018) Multiple Antigen Stimulating Cellular Therapy (MASCT) for hepatocellular carcinoma after curative treatment: A retrospective study. J Cancer 9(8):1385\u20131393. https:\/\/doi.org\/10.7150\/jca.23725","journal-title":"J Cancer"},{"key":"4008_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"BMJ"},{"issue":"1","key":"4008_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3872\/j.issn.1007-385X.2016.01.002","volume":"23","author":"J Huang","year":"2016","unstructured":"Huang J, Hu X, Chen X, Zhang M, Chen F, Guo Y (2016) The safety of multiple antigen stimulating cellular therapy in treating patients with hepatocellular carcinoma. Chin J Cancer Biother 23(1):11\u201316. https:\/\/doi.org\/10.3872\/j.issn.1007-385X.2016.01.002","journal-title":"Chin J Cancer Biother"},{"issue":"5","key":"4008_CR14","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2217\/imt-2020-0278","volume":"13","author":"M Ikeda","year":"2021","unstructured":"Ikeda M, Okusaka T, Ohno I, Mitsunaga S, Kondo S, Ueno H et al (2021) Phase i studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma. Immunotherapy 13(5):371\u2013385. https:\/\/doi.org\/10.2217\/imt-2020-0278","journal-title":"Immunotherapy"},{"issue":"3","key":"4008_CR15","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1053\/j.seminoncol.2012.02.007","volume":"39","author":"BP Keenan","year":"2012","unstructured":"Keenan BP, Jaffee EM (2012) Whole cell vaccines\u2013past progress and future strategies. Semin Oncol 39(3):276\u2013286. https:\/\/doi.org\/10.1053\/j.seminoncol.2012.02.007","journal-title":"Semin Oncol"},{"key":"4008_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.120166","author":"FK Kiani","year":"2021","unstructured":"Kiani FK, Izadi S, Dezfouli EA, Ebrahimi F, Mohammadi M, Chalajour H et al (2021) Simultaneous silencing of A2aR and PD-1 as immune checkpoints by siRNA-loaded nanoparticles enhances the immunotherapeutic potential of dendritic cell vaccine in tumor experimental models. Life Sci. https:\/\/doi.org\/10.1016\/j.lfs.2021.120166","journal-title":"Life Sci"},{"issue":"4","key":"4008_CR17","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3872\/j.issn.1007-385X.2015.04.018","volume":"22","author":"X Kou","year":"2015","unstructured":"Kou X, Huang Y, Yuan Z, Wu M, Qian Q (2015) Efficacy of the combined therapy with autologous dendritic cells-cytokine induced killer cells and percutaneous microwave coagulation for hepatocellular carcinoma. Chin J Cancer Biother 22(4):509\u2013513. https:\/\/doi.org\/10.3872\/j.issn.1007-385X.2015.04.018","journal-title":"Chin J Cancer Biother"},{"issue":"5","key":"4008_CR18","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1158\/1078-0432.ccr-03-0071","volume":"10","author":"M Kuang","year":"2004","unstructured":"Kuang M, Peng BG, Lu MD, Liang LJ, Huang JF, He Q et al (2004) Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res 10(5):1574\u20131579. https:\/\/doi.org\/10.1158\/1078-0432.ccr-03-0071","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4008_CR19","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/01.cji.0000171291.72039.e2","volume":"28","author":"WC Lee","year":"2005","unstructured":"Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF (2005) Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: A clinical trial. J Immunother 28(5):496\u2013504. https:\/\/doi.org\/10.1097\/01.cji.0000171291.72039.e2","journal-title":"J Immunother"},{"issue":"12","key":"4008_CR20","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1038\/bjc.2015.430","volume":"113","author":"J-H Lee","year":"2015","unstructured":"Lee J-H, Lee Y, Lee M, Heo MK, Song J-S, Kim K-H et al (2015) A phase I\/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Br J Cancer 113(12):1666\u20131676. https:\/\/doi.org\/10.1038\/bjc.2015.430","journal-title":"Br J Cancer"},{"key":"4008_CR21","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2017.1328335","author":"J-H Lee","year":"2017","unstructured":"Lee J-H, Tak WY, Lee Y, Heo M-K, Song J-S, Kim H-Y et al (2017) Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phase II study. Oncoimmunology. https:\/\/doi.org\/10.1080\/2162402x.2017.1328335","journal-title":"Oncoimmunology"},{"issue":"2","key":"4008_CR22","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.18632\/oncotarget.20812","volume":"9","author":"H Liu","year":"2018","unstructured":"Liu H, Chen L, Peng Y, Yu S, Liu J, Wu L et al (2018) Dendritic cells loaded with tumor derived exosomes for cancer immunotherapy. Oncotarget 9(2):2887\u20132894. https:\/\/doi.org\/10.18632\/oncotarget.20812","journal-title":"Oncotarget"},{"issue":"4","key":"4008_CR23","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.jhep.2018.12.001","volume":"70","author":"Z Liu","year":"2019","unstructured":"Liu Z, Jiang Y, Yuan H, Fang Q, Cai N, Suo C et al (2019) The trends in incidence of primary liver cancer caused by specific etiologies: results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention. J Hepatol 70(4):674\u2013683. https:\/\/doi.org\/10.1016\/j.jhep.2018.12.001","journal-title":"J Hepatol"},{"issue":"8","key":"4008_CR24","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s00262-015-1709-1","volume":"64","author":"Y Maeda","year":"2015","unstructured":"Maeda Y, Yoshimura K, Matsui H, Shindo Y, Tamesa T, Tokumitsu Y et al (2015) Dendritic cells transfected with heat-shock protein 70 messenger RNA for patients with hepatitis C virus-related hepatocellular carcinoma: a phase 1 dose escalation clinical trial. Cancer Immunol Immunother 64(8):1047\u20131056. https:\/\/doi.org\/10.1007\/s00262-015-1709-1","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"4008_CR25","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1021\/acs.chemrev.9b00472","volume":"120","author":"RJ Malonis","year":"2020","unstructured":"Malonis RJ, Lai JR, Vergnolle O (2020) Peptide-based vaccines: current progress and future challenges. Chem Rev 120(6):3210\u20133229. https:\/\/doi.org\/10.1021\/acs.chemrev.9b00472","journal-title":"Chem Rev"},{"issue":"4","key":"4008_CR26","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s00262-020-02737-y","volume":"70","author":"HM Matsui","year":"2021","unstructured":"Matsui HM, Hazama S, Nakajima M, Xu M, Matsukuma S, Tokumitsu Y et al (2021) Novel adjuvant dendritic cell therapy with transfection of heat-shock protein 70 messenger RNA for patients with hepatocellular carcinoma: a phase I\/II prospective randomized controlled clinical trial. Cancer Immunol Immunother 70(4):945\u2013957. https:\/\/doi.org\/10.1007\/s00262-020-02737-y","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"4008_CR27","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.canlet.2015.08.020","volume":"369","author":"E Mizukoshi","year":"2015","unstructured":"Mizukoshi E, Nakagawa H, Kitahara M, Yamashita T, Arai K, Sunagozaka H et al (2015) Phase I trial of multidrug resistance-associated protein 3-derived peptide in patients with hepatocellular carcinoma. Cancer Lett 369(1):242\u2013249. https:\/\/doi.org\/10.1016\/j.canlet.2015.08.020","journal-title":"Cancer Lett"},{"issue":"7","key":"4008_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"issue":"6","key":"4008_CR29","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1053\/j.gastro.2017.02.001","volume":"152","author":"H Nakagawa","year":"2017","unstructured":"Nakagawa H, Mizukoshi E, Kobayashi E, Tamai T, Hamana H, Ozawa T et al (2017) Association between high-avidity T-cell receptors, induced by \u03b1-fetoprotein-derived peptides, and anti-tumor effects in patients with hepatocellular carcinoma. Gastroenterology 152(6):1395-1406.e1310. https:\/\/doi.org\/10.1053\/j.gastro.2017.02.001","journal-title":"Gastroenterology"},{"issue":"2","key":"4008_CR30","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s12029-015-9690-7","volume":"46","author":"AL Parks","year":"2015","unstructured":"Parks AL, McWhirter RM, Evason K, Kelley RK (2015) Cases of spontaneous tumor regression in hepatobiliary cancers: implications for immunotherapy? J Gastrointest Cancer 46(2):161\u2013165. https:\/\/doi.org\/10.1007\/s12029-015-9690-7","journal-title":"J Gastrointest Cancer"},{"issue":"4","key":"4008_CR31","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1349-7006.2002.tb01265.x","volume":"93","author":"BG Peng","year":"2002","unstructured":"Peng BG, Liu SQ, Kuang M, He Q, Totsuka S, Huang L et al (2002) Autologous fixed tumor vaccine: A formulation with cytokine-microparticles for protective immunity against recurrence of human hepatocellular carcinoma. Jpn J Cancer Res 93(4):363\u2013368. https:\/\/doi.org\/10.1111\/j.1349-7006.2002.tb01265.x","journal-title":"Jpn J Cancer Res"},{"issue":"5","key":"4008_CR32","doi-asserted-by":"publisher","first-page":"700","DOI":"10.3748\/wjg.v11.i5.700","volume":"11","author":"B-G Peng","year":"2005","unstructured":"Peng B-G, Liang L-J, He Q, Kuang M, Lia J-M, Lu M-D et al (2005) Tumor vaccine against recurrence of hepatocellular carcinoma. World J Gastroenterol 11(5):700\u2013704. https:\/\/doi.org\/10.3748\/wjg.v11.i5.700","journal-title":"World J Gastroenterol"},{"issue":"9","key":"4008_CR33","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nm1100","volume":"10","author":"SA Rosenberg","year":"2004","unstructured":"Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10(9):909\u2013915. https:\/\/doi.org\/10.1038\/nm1100","journal-title":"Nat Med"},{"issue":"2","key":"4008_CR34","doi-asserted-by":"publisher","first-page":"443","DOI":"10.4049\/jimmunol.1701024","volume":"200","author":"PM Santos","year":"2018","unstructured":"Santos PM, Butterfield LH (2018) Dendritic cell-based cancer vaccines. J Immunol 200(2):443\u2013449. https:\/\/doi.org\/10.4049\/jimmunol.1701024","journal-title":"J Immunol"},{"issue":"13","key":"4008_CR35","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1158\/1078-0432.CCR-11-3044","volume":"18","author":"Y Sawada","year":"2012","unstructured":"Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y et al (2012) Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: Immunologic evidence and potential for improving overall survival. Clin Cancer Res 18(13):3686\u20133696. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-3044","journal-title":"Clin Cancer Res"},{"key":"4008_CR36","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/b978-0-12-800249-0.00002-0","volume":"121","author":"J Schlom","year":"2014","unstructured":"Schlom J, Hodge JW, Palena C, Tsang KY, Jochems C, Greiner JW et al (2014) Therapeutic cancer vaccines. Adv Cancer Res 121:67\u2013124. https:\/\/doi.org\/10.1016\/b978-0-12-800249-0.00002-0","journal-title":"Adv Cancer Res"},{"key":"4008_CR37","doi-asserted-by":"publisher","DOI":"10.4161\/hv.27678","author":"K Shimizu","year":"2014","unstructured":"Shimizu K, Kotera Y, Aruga A, Takeshita N, Katagiri S, Ariizumi S et al (2014) Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma. Hum Vaccin Immunother. https:\/\/doi.org\/10.4161\/hv.27678","journal-title":"Hum Vaccin Immunother"},{"key":"4008_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"issue":"4","key":"4008_CR39","doi-asserted-by":"publisher","first-page":"16222","DOI":"10.4238\/2015.December.8.12","volume":"14","author":"TY Sun","year":"2015","unstructured":"Sun TY, Yan W, Yang CM, Zhang LF, Tang HL, Chen Y et al (2015a) Clinical research on dendritic cell vaccines to prevent postoperative recurrence and metastasis of liver cancer. Genet Mol Res 14(4):16222\u201316232. https:\/\/doi.org\/10.4238\/2015.December.8.12","journal-title":"Genet Mol Res"},{"issue":"3","key":"4008_CR40","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/cmi.2014.91","volume":"12","author":"C Sun","year":"2015","unstructured":"Sun C, Sun H, Zhang C, Tian Z (2015b) NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma. Cell Mol Immunol 12(3):292\u2013302. https:\/\/doi.org\/10.1038\/cmi.2014.91","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"4008_CR41","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/hep.30347","volume":"70","author":"H Sun","year":"2019","unstructured":"Sun H, Huang Q, Huang M, Wen H, Lin R, Zheng M et al (2019) Human CD96 correlates to natural killer cell exhaustion and predicts the prognosis of human hepatocellular carcinoma. Hepatology 70(1):168\u2013183. https:\/\/doi.org\/10.1002\/hep.30347","journal-title":"Hepatology"},{"issue":"8","key":"4008_CR42","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1111\/cas.14497","volume":"111","author":"M Taniguchi","year":"2020","unstructured":"Taniguchi M, Mizuno S, Yoshikawa T, Fujinami N, Sugimoto M, Kobayashi S et al (2020) Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis. Cancer Sci 111(8):2747\u20132759. https:\/\/doi.org\/10.1111\/cas.14497","journal-title":"Cancer Sci"},{"issue":"7","key":"4008_CR43","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1111\/jgh.15398","volume":"36","author":"CF Teng","year":"2021","unstructured":"Teng CF, Wang T, Shih FY, Shyu WC, Jeng LB (2021) Therapeutic efficacy of dendritic cell vaccine combined with programmed death 1 inhibitor for hepatocellular carcinoma. J Gastroenterol Hepatol 36(7):1988\u20131996. https:\/\/doi.org\/10.1111\/jgh.15398","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"4008_CR44","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3872\/j.issn.1007-385X.2015.06.014","volume":"22","author":"Z Ting","year":"2015","unstructured":"Ting Z, Xiaoxia K, Mengchao W, Qijun Q (2015) Clinical effects of the oxaliplatin-based chemotherapy regimen combined with DC-CIK cells on advanced primary liver carcinoma. Chin J Cancer Biother 22(6):760\u2013764. https:\/\/doi.org\/10.3872\/j.issn.1007-385X.2015.06.014","journal-title":"Chin J Cancer Biother"},{"key":"4008_CR45","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1346764","author":"N Tsuchiya","year":"2017","unstructured":"Tsuchiya N, Yoshikawa T, Fujinami N, Saito K, Mizuno S, Sawada Y et al (2017) Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. OncoImmunology. https:\/\/doi.org\/10.1080\/2162402X.2017.1346764","journal-title":"OncoImmunology"},{"key":"4008_CR46","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.3389\/fimmu.2019.01719","volume":"10","author":"A Xia","year":"2019","unstructured":"Xia A, Zhang Y, Xu J, Yin T, Lu XJ (2019) T Cell Dysfunction in Cancer Immunity and Immunotherapy. Front Immunol 10:1719. https:\/\/doi.org\/10.3389\/fimmu.2019.01719","journal-title":"Front Immunol"},{"key":"4008_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.581270","author":"K Xu","year":"2020","unstructured":"Xu K, Meng Z, Mu X, Sun B, Chai Y (2020) One Single Site Clinical Study: To Evaluate the Safety and Efficacy of Immunotherapy With Autologous Dendritic Cells, Cytokine-Induced Killer Cells in Primary Hepatocellular Carcinoma Patients. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2020.581270","journal-title":"Front Oncol"},{"issue":"6","key":"4008_CR48","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3978\/j.issn.1000-9604.2015.12.07","volume":"27","author":"Y Yi","year":"2015","unstructured":"Yi Y, Han J, Zhao L, Wang C, Fang Y, Wei Q et al (2015) Immune responses of dendritic cells combined with tumor-derived autophagosome vaccine on hepatocellular carcinoma. Chin J Cancer Res 27(6):597\u2013603. https:\/\/doi.org\/10.3978\/j.issn.1000-9604.2015.12.07","journal-title":"Chin J Cancer Res"},{"issue":"4","key":"4008_CR49","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.3892\/etm.2015.2681","volume":"10","author":"MA Yu","year":"2015","unstructured":"Yu MA, Liang P, Yu XL, Han ZY, Dong XJ, Wang Y et al (2015) Multiple courses of immunotherapy with different immune cell types for patients with hepatocellular carcinoma after microwave ablation. Exp Ther Med 10(4):1460\u20131466. https:\/\/doi.org\/10.3892\/etm.2015.2681","journal-title":"Exp Ther Med"},{"issue":"3","key":"4008_CR50","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1440-1746.2009.05784.x","volume":"24","author":"MF Yuen","year":"2009","unstructured":"Yuen MF, Hou JL, Chutaputti A (2009) Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 24(3):346\u2013353. https:\/\/doi.org\/10.1111\/j.1440-1746.2009.05784.x","journal-title":"J Gastroenterol Hepatol"},{"key":"4008_CR51","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/473909","author":"S Yutani","year":"2015","unstructured":"Yutani S, Ueshima K, Abe K, Ishiguro A, Eguchi J, Matsueda S et al (2015) Phase II study of personalized peptide vaccination with both a hepatitis C virus-derived peptide and peptides from tumor-associated antigens for the treatment of HCV-positive advanced hepatocellular carcinoma patients. J Immunol Res. https:\/\/doi.org\/10.1155\/2015\/473909","journal-title":"J Immunol Res"},{"issue":"9","key":"4008_CR52","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1111\/cas.13301","volume":"108","author":"S Yutani","year":"2017","unstructured":"Yutani S, Shirahama T, Muroya D, Matsueda S, Yamaguchi R, Morita M et al (2017) Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies. Cancer Sci 108(9):1732\u20131738. https:\/\/doi.org\/10.1111\/cas.13301","journal-title":"Cancer Sci"},{"issue":"10","key":"4008_CR53","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/cmi.2016.28","volume":"14","author":"QF Zhang","year":"2017","unstructured":"Zhang QF, Yin WW, Xia Y, Yi YY, He QF, Wang X et al (2017) Liver-infiltrating CD11b(-)CD27(-) NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression. Cell Mol Immunol 14(10):819\u2013829. https:\/\/doi.org\/10.1038\/cmi.2016.28","journal-title":"Cell Mol Immunol"},{"issue":"22","key":"4008_CR54","first-page":"2076","volume":"26","author":"Z Zhao","year":"2005","unstructured":"Zhao Z, Yan L, Cui J, Shi J, Long G (2005) HSP-peptide complex vaccine in preventing postoperative recurrence of hepatocarcinoma: 32 cases report. J Fourth Milit Med Univ 26(22):2076\u20132078","journal-title":"J Fourth Milit Med Univ"},{"issue":"24","key":"4008_CR55","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.3969\/j.issn.1000-8179.2009.24.008","volume":"36","author":"G Zhong","year":"2009","unstructured":"Zhong G, Zhang X, Sun Y, Kuang H, Jing X, Min M et al (2009) Effect of autologous tumor cell lysate-ioaded dendritic cell vaccine in combination with cytokine-induced killer cells on hepatocellular carcinoma. Chin J Clin Oncol 36(24):1404\u20131408. https:\/\/doi.org\/10.3969\/j.issn.1000-8179.2009.24.008","journal-title":"Chin J Clin Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04008-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04008-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04008-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T23:59:37Z","timestamp":1679875177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04008-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["4008"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04008-y","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,28]]},"assertion":[{"value":"29 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce material from other sources"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}}]}}